To Determine Bioequivalence Under Fasting Conditions
11
0
0
11
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (11)
Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting Conditions
Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions
Bioavailability Study of Torsemide Tablets Under Fasting Conditions
Bioavailability Study of Tramadol/APAP Tablets Under Fasting Conditions
Bioavailability Study of Clonazepam ODT Under Fasting Conditions
Bioavailability Study of Clonazepam Tablets Under Fasting Conditions
Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions
Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions
Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions
Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting Conditions
Bioavailability Study of Propranolol Under Fasting Conditions